Novogaia
.png)
Novogaia is unlocking nature’s chemistry to develop small-molecule therapeutics against hard-to-drug targets, starting with fungi. While natural products underpin nearly half of approved oral drugs, over 99% of nature’s chemical space remains unexplored. Novogaia is changing that. With advances in computational metabolomics, they’ve built Gaia-01, a foundation model that infers molecular structure directly from mass spectrometry data - bringing scalable drug discovery from nature within reach.
Founders
Tess Bevers is a biochemical engineer who has worked on the origin of life, DNA origami, and molecular dynamics. She sharpened her commercial edge at Morgan Stanley before returning to her scientific roots (or, more fittingly, mycelium), where she is now set on building the world’s first scalable platform for drug discovery from fungi.